1-4 of 4
Jose Lutzky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3352–3361.
https://doi.org/10.1158/1078-0432.CCR-22-3145
Published: 01 September 2023
View articletitled, Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
Open the PDF for Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2289–2296.
https://doi.org/10.1158/1078-0432.CCR-14-1630
Published: 14 May 2015
View articletitled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Open the PDF for Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition in another window
Includes: Supplementary data
Journal Articles

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

John Fruehauf, Jose Lutzky, David McDermott, Charles K. Brown, Jean-Baptiste Meric, Brad Rosbrook, David R. Shalinsky, Katherine F. Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7462–7469.
https://doi.org/10.1158/1078-0432.CCR-11-0534
Published: 30 November 2011
View articletitled, Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
Open the PDF for Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma in another window
Journal Articles

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Kazuo Koyanagi, Steven J. O'Day, Peter Boasberg, Michael B. Atkins, He-Jing Wang, Rene Gonzalez, Karl Lewis, John A. Thompson, Clay M. Anderson, Jose Lutzky, Thomas T. Amatruda, Evan Hersh, Jon Richards, Jeffrey S. Weber, Dave S.B. Hoon
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2402–2408.
https://doi.org/10.1158/1078-0432.CCR-10-0037
Published: 14 April 2010
View articletitled, Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma
Open the PDF for Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma in another window